Cochrane · systematic review · CD012269
Antithrombotic therapy to prevent cognitive decline in people with small vessel disease on neuroimaging but without dementia
Kwan, J, Hafdi, M, Chiang, LL W, et al. · Cochrane Database of Systematic Reviews · 2022 · Cochrane Library
Dementia and Cognitive ImprovementAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
21
current version
GRADE rated
15
No studies
6
Included studies
NR
No studies 6 · 28.6%Ungraded 0 · 0%Very low 11 · 52.4%Low 4 · 19%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Antiplatelet drug compared to placebo in mixed populations (with or without pre‐existing antiplatelet therapy) for the prevention of cognitive decline and dementia in people with cerebral small vessel disease and no dementia
Population: s with mixed prevalence of antiplatelet drug use at baseline, for the prevention of cognitive decline and dementia in people with cerebral small vessel disease and no dementia
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Change in cognitive function from baseline Antiplatelet drug vs placebo | no estimate extracted | 1 study · 280 participants | Very low Downgraded: imprecision |
Incident dementia Antiplatelet drug vs placebo | no estimate extracted | NR | No studies |
Major bleeding (intracranial and extracranial) Antiplatelet drug vs placebo | no estimate extracted | 1 study · 280 participants | Very low Downgraded: imprecision |
Functional ability Antiplatelet drug vs placebo | no estimate extracted | 1 study · 280 participants | Very low Downgraded: imprecision |
Stroke or transient ischaemic attack Antiplatelet drug vs placebo | no estimate extracted | 1 study · 280 participants | Very low Downgraded: imprecision |
Any adverse events (excluding major bleeding) Antiplatelet drug vs placebo | no estimate extracted | 1 study · 280 participants | Very low Downgraded: imprecision |
Withdrawal from study medication Antiplatelet drug vs placebo | no estimate extracted | 1 study · 280 participants | Very low Downgraded: imprecision |
Antiplatelet therapy compared to placebo for prevention of cognitive decline and dementia in people with cerebral small vessel disease and no dementia
Population: s for prevention of cognitive decline and dementia in people with cerebral small vessel disease and no dementia
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Change in cognitive function from baseline Antiplatelet therapy vs placebo | no estimate extracted | 1 study · 50 participants | Very low Downgraded: risk of bias, imprecision |
Incident dementia Antiplatelet therapy vs placebo | no estimate extracted | NR | No studies |
Major bleeding (intracranial and extracranial) Antiplatelet therapy vs placebo | no estimate extracted | NR | No studies |
Functional ability Antiplatelet therapy vs placebo | no estimate extracted | 1 study · 50 participants | Very low Downgraded: risk of bias, imprecision |
Stroke or transient ischaemic attack Antiplatelet therapy vs placebo | no estimate extracted | 1 study · 50 participants | Very low Downgraded: risk of bias, imprecision |
Any adverse events (excluding major bleeding) Antiplatelet therapy vs placebo | no estimate extracted | 1 study · 50 participants | Very low Downgraded: risk of bias, imprecision |
Withdrawal from study medication Antiplatelet therapy vs placebo | no estimate extracted | 1 study · 50 participants | Very low Downgraded: risk of bias, imprecision |
Dual antiplatelet therapy compared to single antiplatelet therapy for prevention of cognitive decline and dementia in people with cerebral small vessel disease and no dementia
Population: people with cerebral small vessel disease and no dementia
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Change in cognitive function from baseline Dual antiplatelet therapy vs single antiplatelet therapy | no estimate extracted | 1 study · 3020 participants | Low Downgraded: imprecision, indirectness |
Incident dementia Dual antiplatelet therapy vs single antiplatelet therapy | no estimate extracted | NR | No studies |
Major bleeding (intracranial and extracranial) Dual antiplatelet therapy vs single antiplatelet therapy | no estimate extracted | 1 study · 3020 participants | Low Downgraded: imprecision, indirectness |
Functional ability Dual antiplatelet therapy vs single antiplatelet therapy | no estimate extracted | NR | No studies |
Stroke or transient ischaemic attack Dual antiplatelet therapy vs single antiplatelet therapy | no estimate extracted | 1 study · 3020 participants | Low Downgraded: imprecision, indirectness |
Any adverse events (excluding major bleeding) Dual antiplatelet therapy vs single antiplatelet therapy | no estimate extracted | NR | No studies |
Withdrawal from study medication Dual antiplatelet therapy vs single antiplatelet therapy | no estimate extracted | 1 study · 3020 participants | Low Downgraded: imprecision, indirectness |